Ebola vaccine ‘safe’

The vaccine is designed to spur the immune system’s production of anti-Ebola antibodies, and people developed them within four weeks of receiving the immunisation at the National Institutes of Health (NIH).

Half of the test group received a higher dose, and those people produced more antibodies, said the study published in the New England Journal of Medicine (NEJM).

Some people also developed a different set of  immune cells, or T cells, the study found. That may be important in fending off Ebola, as prior research found that monkeys protected by the vaccine also had that combination response.

Stimulating both types of immune response is “a promising factor”, said Dr Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), whose employees led the work.

The researchers reported no serious side effects. But two people who received the higher-dose vaccine